Organization

Cognition Therapeutics, Inc.

About

Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics targeting age-related degenerative diseases and disorders specific to the central nervous system, or CNS, and retina with a goal to develop treatments that can modify the diseases in patients with these disorders. The company has expert experience in the σ-2 (sigma-2) receptor, or S2R, which is expressed by multiple cell types, including neuronal synapses. It also acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina.

Overview

Founded 2007
Type Public
Location Pennsylvania, USA Purchase, Harrison, New York, USA

Stock

CGTX $1.98 13.79% $0.24

Latest News

Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday Sep 30, 2022 Benzinga Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock...
Why Sunlight Financial Shares Are Trading Lower By 59%, Here Are 54 Stocks Moving In Thursday's Mid-Day Session Sep 29, 2022 Benzinga Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares jumped 52% to $2.1325 after B of A Securities initiated coverage on the stock with a Buy rating...
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022 Sep 29, 2022 Benzinga Upgrades For Charter Communications Inc (NASDAQ:CHTR), Wolfe Research upgraded the previous rating of Underperform to Peer Perform. For the second quarter, Charter Communications had an...
Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference Sep 29, 2022 GlobeNewswire Inc. PURCHASE, N.Y., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery...
Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial Sep 27, 2022 GlobeNewswire Inc. PURCHASE, N.Y., Sept. 27, 2022 (GLOBE NEWSWIRE) --  Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today that the company has received a $2.14M grant award from...